Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
March 2016, Vol 7, No 2
March 2016, Vol 7, No 2
First-in-Human CAR T-Cell Trial Demonstrates Activity in Multiple Myeloma
By
Dana Taylor
Emerging Therapies
,
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
March 2016, Vol 7, No 2
Chimeric antigen receptor (CAR) T-cell therapy has been striking in various hematologic malignancies, and for the first time this treatment approach is being evaluated in multiple myeloma.
Read Article
Inotuzumab Ozogamicin Shows Promise in Older Patients with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
March 2016, Vol 7, No 2
Elderly patients with Philadelphia-negative B-cell acute lymphoblastic leukemia (ALL) have overall poor outcomes with current therapies. Results of a new study presented at ASH 2015 suggest that frontline treatment with the investigational antibody-drug conjugate inotuzumab ozogamicin in combination with deintensified chemotherapy is a good option for older patients with this disease.
Read Article
Biomarker Panel May Aid Early Detection of Colorectal Cancer
By
Charles Bankhead
Colorectal Cancer
,
Personalized Medicine
,
Solid Tumors
March 2016, Vol 7, No 2
A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colorectal cancer (CRC). The panel yielded a negative predictive value exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and colorectal plus other cancers. The biomarker assay demonstrated fair to good performance characteristics, associated with the receiver operating characteristic (ROC) curve ranging between 0.70 and 0.80.
Read Article
Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer, according to the results of a study presented by Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, NY, at the 2016 ASCO Genitourinary Cancers Symposium.
Read Article
In the Literature - March 2016
In the Literature
March 2016, Vol 7, No 2
Read Article
FDA News - March 2016
FDA Approvals, News & Updates
,
In the News
March 2016, Vol 7, No 2
Read Article
Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Cancer
By
Charles Bankhead
Emerging Therapies
,
Personalized Medicine
March 2016, Vol 7, No 2
Patients with previously treated metastatic urothelial cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab led to an overall response rate of 15% in 311 patients, including a 26% rate among patients who had the highest levels of PD-L1 expression. Historical data have demonstrated response rates of about 10% for second-line therapy and beyond.
Read Article
A 3-Drug Regimen the Preferred Approach in Newly Diagnosed Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
March 2016, Vol 7, No 2
Although the cost of treating newly diagnosed patients with multiple myeloma is greatly increased with the use of 3 drugs, 2-drug regimens should no longer be considered adequate, according to new data presented at ASH 2015.
Read Article
Anthem’s Response to Survivorship Medicine: Reimbursement Based on Care Coordination and Patient Outcomes
By
Chase Doyle
Survivorship
,
Policies & Guidelines
March 2016, Vol 7, No 2
Survivorship medicine has never been in more demand, but questions regarding reimbursement remain. According to
Jennifer Malin, MD, PhD
, Medical Director, Oncology and Care Management, Anthem, if cancer survivorship models are to succeed, they will need to integrate into new healthcare delivery models, with less focus on cost and more on improving care coordination.
Read Article
Online First
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
By
Al B. Benson III, MD
;
Robert W. Carlson, MD
March 2016, Vol 7, No 2
A recently published perspective in
Value-Based Cancer Care
criticized the National Comprehensive Cancer Network (NCCN) Evidence Blocks initiative. Regrettably, that perspective is extremely misleading and is full of innuendo and misuse of statistics.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma